Constraints on the efficacy of mucosal tolerance in treatment of human and animal arthritic diseases.
Mucosal administration of an autoantigen has been shown to be a powerful way of inducing tolerance in both animal and human arthritis clinical trials. Bovine or chicken type II collagen has been administered orally to rheumatoid arthritis patients, resulting in some, although in many cases rather limited, clinical improvement. Animal studies have revealed that the mechanisms that underlie induction of mucosal tolerance include clonal deletion, suppression of the proinflammatory Th1 cells, and the induction of regulatory T cells. These cells, defined as a persistently CD25-expressing subset of CD4(+) cells, are frequently anergic, may produce anti-inflammatory cytokines such as IL-10 and TGF-beta, and are likely to be agents of bystander suppression. A key feature that may affect the induction of these cells and other suppressive mechanisms is the dose of antigen administered. The results from human clinical trials suggest a daily dose of significantly less than 1 mg is optimal. Similarly data from collagen-induced arthritis studies reveal an optimal dose above and below which there is little or no immune suppression. Indeed, the incorrect dose can prime the immune response and aggravate disease. The timing and frequency of administration is also vital to the level of immune tolerance induced and the control of the pathological process. This and other findings derived from animal studies are discussed here in relation to the results from human clinical trials.
Staines
Norman A
NA
Infection and Immunity Research Group, King's College London, Stamford Street, London, SE1 9NN, UK. norman.staines@kcl.ac.uk
Derry
Catherine J
CJ
Marinova-Mutafchieva
Lilia
L
Ali
Nadira
N
Davies
D Huw
DH
Murphy
John J
JJ
D000818:Animals; D000941:Antigens / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000276:immunology* / Q000628:therapy; D001402:B-Lymphocytes / Q000276:immunology*; D002417:Cattle; D002645:Chickens; D002986:Clinical Trials as Topic; D003094:Collagen / Q000276:immunology / Q000627:therapeutic use*; D004195:Disease Models, Animal; D006801:Humans; D018928:Immunity, Mucosal; D013601:T-Lymphocytes / Q000276:immunology*
D000941:Antigens; D003094:Collagen